Dear Colleagues
Coming February 2026: The 6th Annual OncoAlert Colloquium 🚨
REGISTER👉 oncoalert.m-pages.com/7I0mwF/the-2...
As ALWAYS ✅Patients Included
#BreastCancer Day Feb 3, 2026
@hoperugo.bsky.social 🇺🇸
@erikahamilton9.bsky.social 🇺🇸
@drsgraff.bsky.social 🇺🇸
@elisaagostinetto.bsky.social 🇧🇪
Colleagues, the Complete #ESMO25 OncoAlert Newsletter is coming Oct 27‼️ GET IT HERE👉 oncoalert.m-pages.com/nhMpwe/oncoa...
50 of our PICKS of TOP Trials out of Berlin 🇩🇪
@elisaagostinetto.bsky.social @elisabettabonzano.bsky.social @erikahamilton9.bsky.social @maryamlustberg.bsky.social
Oncology Here & NOW S2E3 in #BreastCancer
with @elisaagostinetto.bsky.social & @erikahamilton9.bsky.social discussing:
✅Current & emerging treatments
✅Patient selection
✅T-DXd + pertuzumab
✅ILD management & more
@hoperugo.bsky.social @elisabettabonzano.bsky.social
youtu.be/YdUX52c22Ig
The OncoAlert Breast Cancer Faculty, led by Dr. Elisa Agostinetto🇧🇪 , has selected the OncoAlert🚨 TOP 🔟 #BreastCancer Abstracts to be presented at #ESMO25 in Berlin
I am thrilled to start the #ESMO Leadership Program 2025/26 with such an amazing class of colleagues from all over the world! 🌎
Truly honored for being selected for this prestigious program and looking forward to #ESMO25 to start this journey together🚀
@myesmo.bsky.social @oncoalert.bsky.social
#ResearchHighlight
In a study published in #Cell, Phelps et al. find a mechanism connecting exercise, gut microbiota & anti-tumour immunity; exercise induces microbiota to produce formate, which in turn enhances CD8+ T cell functionality.
👇
The OncoAlert WEEKLY RoundUp 🚨
Covering TOP of the week July 11-17
www.youtube.com/watch?v=N9lO...
REGISTER👉 www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@realbowtiedoc.bsky.social
@drnataliagandur.bsky.social
📣Highlights from #ESMO Breast Cancer 2025 Satellite Symposium
Experts discuss treatment strategies/sequencing after ET+CDK4/6i for ER+/HER2- metastatic #breastcancer
cor2ed.com/n-connect/pr...
This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only
The OncoAlert🚨NEWSLETTER
⭐️COMPLETE #ASCO25 EDITION
⭐️REGISTER
👉 oncoalert360.com
👉 buff.ly/48Xpgz0
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@maryamlustberg.bsky.social
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@drnataliagandur.bsky.social
@hoperugo.bsky.social
ECO & IPOS bring you a powerful online roundtable exploring how empathy shapes cancer care, and how we can better support the professionals delivering it.
Join the discussion on 🗓️ Tuesday, 25 June at 🕓 16:00–17:30 CEST.
Register now 🔗 www.europeancancer.org/events/363:y...
Are you a young oncologist attending #ASCO25?
Join us on Monday, June 2 to talk about the Keys to Success for the Early Career Oncologist! 🔑 💫
Check here the sessions scheduled at the Trainee & Early Career Lounge: cdn.bfldr.com/KOIHB2Q3/as/...
@oncoalert.bsky.social
@ascocancer.bsky.social
The #ASCO25 #OncoAlertTOP10 Abstracts in #BreastCancer
These are some of our picks of TOP abstracts we look forward to be presented at the upcoming ASCO Meeting in Chicago🇺🇸
@elisaagostinetto.bsky.social
@erikahamilton9.bsky.social
@drsgraff.bsky.social
@elisabettabonzano.bsky.social
The OncoAlert🚨ROUND UP Now Out‼️
Covering May 15-22, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/xgIw0BISCpo
@elisaagostinetto.bsky.social
@barbaramelao.bsky.social
@elisaagostinetto.bsky.social
@icromeattini.bsky.social
@realbowtiedoc.bsky.social
The VJ OA Oncology Journal Club
Dr. Evandro de Azambuja discussing APHINITY in #BreastCancer now on APPLE PODCASTS
podcasts.apple.com/se/podcast/o...
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@icromeattini.bsky.social
@maryamlustberg.bsky.social
The @OncoAlert 🚨 @VJOncology JOURNAL CLUB
Today we present @E_de_Azambuja 🇧🇪of @JulesBordet who talks to us about the Final Analysis of the APHINITY trial just Presented at #ESMOBreast25
youtu.be/ydcXe_faQH0
A sub analysis was just published out on European Journal of Cancer:
#ESMOBreast25 @laubdh.bsky.social from Institut Jules Bordet on the role of immunotherapy in ER+/HER2- early breast cancer #ESMOAmbassadors @myesmo.bsky.social
Right before the start of #ESMOBreast25, our last article is now out in #EJC
In this sub-analysis of the APHINITY trial led by @ChiaraDauccia, overweight/obesity was associated with poorer survival outcomes
50-days free access link👇🏻
authors.elsevier.com/a/1l5DL3QE--...
@oncoalert.bsky.social
The OncoAlert🚨Newsletter Now Out Covering May 2-8, 2025
REGISTER at www.OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
✅DESTINY-Breast11 Update from Industry
✅PEACE V STORM in #Prostate Cancer⛈️🕊️☢️
✅OS🧬EGFR-mutant Advanced🫁Non-Small Cell #LungCancer Treated with 1L Osimertinib
and more
Association between risk-reducing surgeries and survival in young BRCA carriers with breast cancer: an international cohort study
www.thelancet.com/journals/lan...
Findings provide robust evidence to guide counselling and management decisions for young BRCA carriers with prior breast cancer
NEWS FROM INDUSTRY🚨 Source AstraZeneca
DESTINY-Breast11 Update
DESTINY-Breast11 sees trastuzumab deruxtecan followed by paclitaxel, trastuzumab, and pertuzumab improved pathologic complete response rates compared to the standard neoadjuvant regimen
www.astrazeneca.com/media-centre...
Join @OncoAlert 🚨& @VJOncology Journal Club Discussing : Assisted reproductive technology in young BRCA carriers with a pregnancy after #BreastCancer
podcasts.apple.com/se/podcast/o...
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
@realbowtiedoc.bsky.social
Join Us at Oncology Here & Now
www.oncoalert360.com/12789765039p...
@elisaagostinetto.bsky.social @realbowtiedoc.bsky.social @biagioricciutimd.bsky.social @barbaramelao.bsky.social
@weoncologists.bsky.social @drsgraff.bsky.social @erikahamilton9.bsky.social
I am so grateful that our work has been awarded with a #ConquerCancer #ASCO Merit Award! 💫
Proud to be on this list for the third time, a big thank goes to my mentors and co-authors - Looking forward to presenting our work in Chicago!🇧🇪✈️🇺🇸
@oncoalert.bsky.social
Extended adjuvant endocrine therapy for HR+/HER2-neg #breastcancer is a highly debated topic
Supporting the choice of prolonged treatment means balancing the QoL against the costs of toxicity
In this review we address this topic👇🏻
@oncoalert.bsky.social
www.sciencedirect.com/science/arti...
The OncoAlert🚨Weekly Round Up Covering the TOP of the week April 4-10, 2025
REGISTER at oncoalert360.com OR oncoalert.m-pages.com/nhMpwe/oncoa...
youtu.be/l_jcTe69cCs
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
Now out our work on a large cohort (n=859‼️) of patients with #breastcancer and leptomeningeal metastases🧠
Happy to share that our work results from an international collaboration of young oncologists committed to advance cancer research👇🏻
@oncoalert.bsky.social
doi.org/10.1016/j.br...
Oncology HERE & NOW Webcast/Podcast Now Out
JOIN Faulty 🚨 @realbowtiedoc.bsky.social 🇺🇸&
@crisbergerot.bsky.social 🇧🇷 as they dive into #SupportiveCare , the future of #Telemedicine and much more!
youtu.be/4WYdTostU7w
Effect of BMI on #BreastCancer stage and #BreastCancer specific survival
link.springer.com/article/10.1...
Findings highlight the need for more comprehensive assessments of body composition and metabolic health in BC patients.
@elisaagostinetto.bsky.social
@elisabettabonzano.bsky.social
Now out a new episode of Oncology Here&Now, a podcast by @oncoalert.bsky.social 🎙️
I had the pleasure to discuss with @maryamlustberg.bsky.social about adjuvant CDK4/6i, including:
🔸how to choose between abema and ribo
🔸how to manage progression during or after adj CDK4/6i
🔸Male breast cancer!
